Table 2

Reductions in DAS28 at 3 and 6 months (mean (SD)) and achievement of EULAR good/moderate response (%) by RF and anti-CCP status

PositiveNegativep ValuePositiveNegativep Value
DAS28 improvement at 3 months (N=1073)DAS28 improvement at 6 months (N=930)
RF1.8 (1.3)1.4 (1.3)0.00051.9 (1.5)1.6 (1.5)0.009
Anti-CCP1.9 (1.4)1.1 (1.3)<0.00012.0 (1.5)1.4 (1.6)0.002
Double1.9 (1.4)0.9 (1.1)<0.00012.1 (1.5)1.1 (1.6)0.001
EULAR good/moderate response at 3 months (N=1087)EULAR good/moderate response at 6 months (N=945)
RF17.7/45.9%15.0/39.2%0.1023.3/42.9%20/37.9%0.17
Anti-CCP20.2/47.9%6.4/39.4%<0.000125.7/42.5%14.5/39.1%0.05
Double20.4/47.8%4.4/37.8%0.00125.5/43.6%15.2/36.4%0.13
  • N = total number of patients for whom data on DAS28 improvement/EULAR response at 3 and 6 months were available.

  • anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, 28-joint count Disease Activity Score; EULAR, European League Against Rheumatism; RF, rheumatoid factor.